Geneva: China National Pharmaceutical Group and China Kexing company have submitted data on two new coronal vaccines developed by them to the WHO for evaluation of the WHO emergency use list, experts from the World Health Organization said on the 26th.
Katherine O’Brien, director of immunization, vaccines and biological products of who, said at the press conference that there are two kinds of Chinese vaccine products being assessed by who’s emergency use list, namely, Xinguan inactivated vaccine from Sinopharm group and China Kexing company.
O’Brien said the who also expects China’s new vaccine data to pass the organization’s policy assessment. Unlike the emergency use list assessment from the WHO vaccine regulatory authority, the policy assessment is conducted separately by the WHO Strategic Advisory Panel on immunization, which will make recommendations on how to use the relevant vaccines. Previously, the expert group has carried out policy evaluation on Pfizer’s and Modena’s vaccines and given suggestions on their use.
According to the latest WHO documents, Sinopharm vaccine is in the process of who emergency use list evaluation. Kexing company has submitted vaccine evaluation data in mid January, and more documents are expected to be submitted by the end of this month. The final evaluation results of the two vaccines are expected to be released as early as March.
In addition, Seth Berkeley, CEO of GAVI, praised China’s efforts in the new vaccine at the press conference. The China novel coronavirus pneumonia vaccine implementation plan (COVAX) was introduced to China early, he said. “China has submitted some data on the (New) vaccine to who for prequalification. This is an important step and we will continue our dialogue with China. If people are interested in getting these vaccines, and the data shows that they can bring value to the (covax) vaccine portfolio, then we will promote cooperation with these (Chinese) companies. ” Berkeley said.